Public Market Listing
9926HKEX
Live quotes, historical charts, and market capitalization for Akeso are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(11 total)
11Total Assets
0Approved
7Phase 3 / Filed
4Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1×CTLA-4Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | CD47Monoclonal antibody | Acute Myeloid Leukemia | |
| Phase 3 | IL-12/23 p40Monoclonal antibody | Psoriasis | |
| Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | PD-1 + VEGFAMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisAsthma | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | IL-4 receptor alpha / ST2Multispecific antibody | Asthma | |
| Phase 2 | TROP2 / Nectin-4 (dual)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1/2 | PD-1 x LAG-3Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 1/2 | HER3Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.